CPT 79101 Radiopharmaceutical IV Therapy Reimbursement

CPT code 79101 denotes the intravenous administration of a radiopharmaceutical for therapeutic purposes. As a procedure code for systemic delivery of radioactive agents, it is used in nuclear medicine and oncology settings where targeted radiation therapy via the bloodstream is required. The code matters nationally because radiopharmaceutical therapies are increasingly used for certain cancers and systemic conditions, carry specific site-of-service considerations, and interact with payer coverage policies and specialty pharmacy workflows.

Key payers typically involved in coverage and reimbursement for this service include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. This publication provides a concise overview of CPT code 79101, including clinical context, typical sites of service, commonly applied billing modifiers (listed separately), and expected interactions with payer policies.

Readers will learn the clinical intent of the code, where the service is commonly performed, and what types of benchmarks and policy areas to review when managing claims for radiopharmaceutical intravenous therapy. Data elements not provided in the input are noted as unavailable; the content focuses on describing the code, its clinical application, and payer coverage scope at a national level.

Billing Code Overview

CPT code 79101 describes an injectable therapeutic procedure in which a provider administers a radiopharmaceutical substance into the venous bloodstream to treat a patient’s condition. This is a radiopharmaceutical intravenous therapeutic injection used when a systemic delivery of radioactive medication is required for treatment rather than diagnostic imaging.

Service type: Therapeutic radiopharmaceutical administration (intravenous)

Typical site of service: Hospital outpatient department, outpatient infusion center, or specialized nuclear medicine clinic

Data not available in the input.

Clinical Context

A 65-year-old patient with metastatic thyroid carcinoma presents for systemic radionuclide therapy. After review of recent labs, pregnancy status, and patient consent, the nuclear medicine team prepares a therapeutic dose of a radiopharmaceutical for intravenous administration. The patient is placed in a monitored treatment room in the outpatient nuclear medicine or radiation oncology suite. A registered nurse or nuclear medicine technologist verifies identity, explains the procedure, and establishes venous access. The provider (nuclear medicine physician or radiation oncologist) confirms indication, ensures radiation safety measures, and injects the radiopharmaceutical into the venous bloodstream under standard precautions. Post-injection monitoring is performed to assess for immediate adverse reactions, and discharge instructions include radiation safety precautions, potential side effects, and follow-up imaging or labs as indicated.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when reporting only the physician's professional interpretation or oversight when technical component is billed separately
`59`	Distinct procedural service

Taxonomy Code	Specialty	Notes
2085S0003X	Nuclear Medicine Physician	Primary specialist for therapeutic radiopharmaceutical administration and oversight
2086S0126X	Radiation Oncology	Manages therapeutic radionuclide treatments and follow-up
207RG0200X	Internal Medicine / Endocrinology	Often coordinates care for thyroid-related radionuclide therapy and medical management

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C73`	Malignant neoplasm of thyroid gland	Common indication for therapeutic radioactive iodine and other radionuclide treatments
`C79.9`	Secondary malignant neoplasm of unspecified site	Metastatic disease that may be treated with systemic radiopharmaceuticals for symptom control or tumor burden reduction
`D09.3`	Carcinoma in situ of thyroid	Pre-treatment evaluation and potential therapeutic considerations in selected scenarios
`E05.90`	Thyrotoxicosis, unspecified without thyrotoxic crisis or storm	Thyroid functional status assessment is relevant prior to radioactive iodine therapy
`M51.26`	Other intervertebral disc displacement, lumbar region	Example of metastatic spine disease symptoms where radiopharmaceutical therapy may be considered as part of systemic management

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`79101`	Injection of radiopharmaceutical into venous blood stream for therapeutic purposes	Primary procedure: intravenous administration of a therapeutic radiopharmaceutical
`77520`	Radiotherapy procedure planning, complex, including simulation and dosimetry	Performed prior to radionuclide therapy when dosimetry or complex planning is required
`79005`	Radiopharmaceutical therapy, including preparation and administration, unlisted dose/technique	Alternate code used for certain therapeutic radiopharmaceutical administrations not otherwise specified
`96413`	Chemotherapy administration, injection, IV push, each additional drug (Note: chemotherapy administration codes sometimes billed alongside systemic oncologic therapies)	Used when concurrent IV chemotherapy is administered in addition to radionuclide therapy
`99070`	Supplies and materials provided by the physician over and above those usually included with the office visit or service	Used to report special protective materials, isolation supplies, or additional disposables required for radiopharmaceutical therapy

OpenPayer

Summary & Overview

CPT 79101: Intravenous Radiopharmaceutical Therapeutic Injection